{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [{"AbstractText": ["Estrogenic compounds are the most important group of drugs that can induce hypertension. Studies have shown an incidence of significant hypertension amounting to less than 1% after 1 year of taking oral contraceptives and about 2% after 5 years. The ratio of the incidence of hypertension among ''takers'' to that of ''nontakers'' has been assessed at 1.8 by 1 study and 2.6 by another. Small but significant increments in systolic and diastolic pressures can be discerned during the first 2 years of treatment. Cessation of treatment has resulted in pressures returing to pretreatment levels within 3 months. In those previously normal the highest readings during oral contraceptive use were only 155/90 mm of Hg. Severe hypertension is more likely to occur in the predisposed, and malignant hypertension has been reported. Previous hypertension, toxemia of pregnancy, obesity, and nephropathy are predisposing conditions. Although progestagens, used alone, do not cause clinical hypertension the incidence of hypertension associated with an estrogen-progestogen combination was directly related to the dose of progestagen used. Weight gain is often observed in oral contraceptive users and is occasionally accompanied by edema and hypertension. There is a marked increase in the circulating level of renin substrate (angiotensinogen) which is caused by the estrogen component of the pill. The increase in renin substrate is associated with increase in plasma levels of renin activity, angiotensin 2, and aldosterone, together with a fall in plasma renin concentration. The suppression of plasma renin concentration can persist for weeks after stopping the pill. The factors responsible for hypertension are probably intrinsic and may be either neural, vascular, or renal. Patients taking oral contraceptives should have blood pressure checks at 6-month intervals, and more frequently in high risk cases. In the management of those with only mild blood pressure elevation, such patients should change to a preparation with the lowest available estrogen dosage, 30 mcg of ethinyl estradiol, or reserve the method for use during crucial periods of family planning. With moderate hypertension the oral contraceptive should be suspended for 3-6 months. If the blood pressure falls, oral contraceptives should not be resumed but another method recommended. Continuing hypertension requires further study and possibly elective sterilization. Severe hypertension requires withdrawal of the pill, urgent investigation, and treatment. Other drugs may cause hypertension. Management of these patients is outlined. Structural formulae of progesterone, norethisterone acetate, medroxyprogesterone acetate, and norgestrel are shown."]}], "CitationSubset": ["IM"], "OtherID": ["763433", "00036227"], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [["Adrenal Cortex Hormones", "Age Factors", "Biology", "Contraception", "Contraceptive Agents, Estrogen--side effects", "Contraceptive Agents, Female--side effects", "Contraceptive Agents, Progestin--side effects", "Contraceptive Agents--side effects", "Contraceptive Methods--side effects", "Diseases", "Edema", "Family Planning", "Homeostasis", "Hypertension", "Incidence", "Measurement", "Medroxyprogesterone Acetate", "Norethindrone Acetate", "Norgestrel", "Obesity", "Oral Contraceptives, Combined", "Oral Contraceptives--side effects", "Parity", "Physiology", "Progesterone", "Renin-angiotensin-aldosterone Effects", "Research Methodology", "Vascular Diseases"]], "InvestigatorList": [], "PMID": "185040", "DateCompleted": {"Year": "1976", "Month": "12", "Day": "30"}, "DateRevised": {"Year": "2018", "Month": "11", "Day": "13"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0012-6667", "JournalIssue": {"Volume": "12", "Issue": "3", "PubDate": {"Year": "1976"}}, "Title": "Drugs", "ISOAbbreviation": "Drugs"}, "ArticleTitle": "Drug-induced hypertension: pathogenesis and management.", "Pagination": {"StartPage": "222", "EndPage": "230", "MedlinePgn": "222-30"}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [], "LastName": "Stokes", "ForeName": "G S", "Initials": "GS"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Drugs", "NlmUniqueID": "7600076", "ISSNLinking": "0012-6667"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antidepressive Agents, Tricyclic"}, {"RegistryNumber": "0", "NameOfSubstance": "Contraceptives, Oral, Hormonal"}, {"RegistryNumber": "0", "NameOfSubstance": "Estrogens"}, {"RegistryNumber": "0", "NameOfSubstance": "Monoamine Oxidase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Progestins"}, {"RegistryNumber": "0", "NameOfSubstance": "Sympathomimetics"}, {"RegistryNumber": "059QF0KO0R", "NameOfSubstance": "Water"}, {"RegistryNumber": "11128-99-7", "NameOfSubstance": "Angiotensin II"}, {"RegistryNumber": "4964P6T9RB", "NameOfSubstance": "Aldosterone"}, {"RegistryNumber": "9002-60-2", "NameOfSubstance": "Adrenocorticotropic Hormone"}, {"RegistryNumber": "9NEZ333N27", "NameOfSubstance": "Sodium"}, {"RegistryNumber": "EC 3.4.23.15", "NameOfSubstance": "Renin"}, {"RegistryNumber": "MM6384NG73", "NameOfSubstance": "Carbenoxolone"}, {"RegistryNumber": "MN3L5RMN02", "NameOfSubstance": "Clonidine"}, {"RegistryNumber": "V27W9254FZ", "NameOfSubstance": "Cortisone"}], "MeshHeadingList": [{"QualifierName": ["adverse effects"], "DescriptorName": "Adrenocorticotropic Hormone"}, {"QualifierName": ["physiology"], "DescriptorName": "Aldosterone"}, {"QualifierName": ["physiology"], "DescriptorName": "Angiotensin II"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Antidepressive Agents, Tricyclic"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Carbenoxolone"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Clonidine"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Contraceptives, Oral, Hormonal"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Cortisone"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Estrogens"}, {"QualifierName": [], "DescriptorName": "Glycyrrhiza"}, {"QualifierName": ["drug effects"], "DescriptorName": "Hemodynamics"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemically induced", "epidemiology", "physiopathology", "prevention & control"], "DescriptorName": "Hypertension"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Monoamine Oxidase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Progestins"}, {"QualifierName": ["physiology"], "DescriptorName": "Renin"}, {"QualifierName": ["metabolism"], "DescriptorName": "Sodium"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Sympathomimetics"}, {"QualifierName": ["metabolism"], "DescriptorName": "Water"}], "NumberOfReferences": "34"}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Med J Aust. 1973 Sep 15;2(11):529-33", "ArticleIdList": ["4748579"]}, {"Citation": "Endocrinology. 1952 Nov;51(5):421-6", "ArticleIdList": ["13010197"]}, {"Citation": "Br Med J. 1975 Nov 8;4(5992):326-7", "ArticleIdList": ["1192051"]}, {"Citation": "J Obstet Gynaecol Br Commonw. 1970 Nov;77(11):1007-12", "ArticleIdList": ["4320691"]}, {"Citation": "Am J Obstet Gynecol. 1968 Mar 15;100(6):875-7", "ArticleIdList": ["5642586"]}, {"Citation": "Br Med J. 1974 Mar 23;1(5907):533-5", "ArticleIdList": ["4817186"]}, {"Citation": "Aust N Z J Obstet Gynaecol. 1971 Aug;11(3):148-56", "ArticleIdList": ["5286756"]}, {"Citation": "Ann Intern Med. 1972 Jul;77(1):83-5", "ArticleIdList": ["4559540"]}, {"Citation": "Gut. 1968 Feb;9(1):42-5", "ArticleIdList": ["5640925"]}, {"Citation": "Br Med J. 1973 Mar 3;1(5852):522-3", "ArticleIdList": ["4571186"]}, {"Citation": "Lancet. 1969 Aug 30;2(7618):466-7", "ArticleIdList": ["4183908"]}, {"Citation": "Practitioner. 1970 Jul;205(225):58-64", "ArticleIdList": ["5479578"]}, {"Citation": "Br Heart J. 1972 Dec;34(12):1238-43", "ArticleIdList": ["4647097"]}, {"Citation": "Circulation. 1975 May;51(5):916-23", "ArticleIdList": ["1122595"]}, {"Citation": "J Clin Invest. 1956 Apr;35(4):423-9", "ArticleIdList": ["13306784"]}, {"Citation": "Science. 1937 Jul 9;86(2219):40-1", "ArticleIdList": ["17813222"]}, {"Citation": "Aust N Z J Med. 1971 Feb;1(1):49-52", "ArticleIdList": ["4935625"]}, {"Citation": "Br Heart J. 1975 Mar;37(3):336-8", "ArticleIdList": ["1138738"]}, {"Citation": "Am J Physiol. 1972 Jul;223(1):194-7", "ArticleIdList": ["5039063"]}, {"Citation": "Lancet. 1969 Dec 13;2(7633):1300-1", "ArticleIdList": ["4188004"]}, {"Citation": "J Clin Endocrinol Metab. 1972 Jun;34(6):1067-73", "ArticleIdList": ["4336457"]}, {"Citation": "Am J Obstet Gynecol. 1972 Apr 1;112(7):912-9", "ArticleIdList": ["4114467"]}, {"Citation": "Am Heart J. 1973 May;85(5):605-10", "ArticleIdList": ["4697628"]}, {"Citation": "Ann Intern Med. 1971 Jan;74(1):13-21", "ArticleIdList": ["4321709"]}, {"Citation": "Br Med J. 1973 Aug 11;3(5875):317-20", "ArticleIdList": ["4723812"]}, {"Citation": "JAMA. 1972 Dec 18;222(12):1507-10", "ArticleIdList": ["4678420"]}, {"Citation": "Br Med J. 1973 May 19;2(5863):389-92", "ArticleIdList": ["4574044"]}, {"Citation": "J Clin Invest. 1970 Aug;49(8):1596-604", "ArticleIdList": ["5431666"]}, {"Citation": "Clin Sci. 1969 Feb;36(1):67-76", "ArticleIdList": ["4306500"]}, {"Citation": "JAMA. 1968 Aug 12;205(7):492-6", "ArticleIdList": ["5695305"]}], "ReferenceList": []}], "History": [{"Year": "1976", "Month": "1", "Day": "1"}, {"Year": "1976", "Month": "1", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1976", "Month": "1", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["185040", "10.2165/00003495-197612030-00005"]}}]}